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Introduction
Port wine stain (PWS) is a congenital, progressive vascular 
malformation of human skin involving a superficial 
vascular plexus with an occurrence of 3~5 children per 
1000 live births.1-3 Personality development is adversely 
affected in patients since most malformations occur on 
the face. Low self-esteem in such patients and problems 
with interpersonal relationships have been reported 
in many studies.4-6 The pathogenesis of PWS remains 
incompletely understood. A sporadic somatic guanine 
nucleotide-binding protein, G alpha subunit q (GNAQ) 
mutation (R183Q), has been identified in PWS lesions 
with an average mutation frequency lower than 5%.7,8 
Tan et al have further found that the c-Jun N-terminal 
kinases and extracellular signal regulated kinases are 
consecutively activated in both infantile and adult PWS 
blood vessels,9 which may partially be a result from 
GNAQ mutation (R183Q) in a subset of PWS patients.10 
The dilation of PWS blood vessels in patients is 
progressive with aging: PWS lesions are flat red macules 
in childhood, but become darken to purple, and often 
develop into vascular nodules by middle ages.11,12 Pulsed 
dye laser (PDL) is the current standard treatment for 
PWS, which converts incoming photo energy to heat, thus 
inducing blood vessel wall necrosis.13-19 However, PDL 
usually induces some acute adverse effects on patients 
after laser treatment, including pain, erythema, scabbing 
and swelling. These adverse effects cause discomfort 
to patients, especially infantile and pediatric subjects. 
Therefore, efficient reduction of these adverse effects is 
very important for post-PDL care of those young subjects. 
Numerous types of corticosteroids have been used with 
PDL to reduce the post-PDL inflammatory response or 
prevent scar formation.20-22 However, high incidence of 
adverse sequelae following application of intralesional 
corticosteroid (triamcinolone acetonide, 5-FU)20 
and high cost of these agents to many impoverished 
patients visiting our clinic have driven us to look for a 
more affordable corticosteroid with fewer side effects. 
Halometasone is a low-cost synthetic tri-halogenated 
corticosteroid that shows anti-inflammatory properties 
in treating dermatitis and chronic psoriasis vulgaris.23,24 
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Abstract
Introduction: Pulsed dye laser (PDL) for treatment of port wine stain (PWS) usually causes some 
acute adverse effects, including pain, erythema, scabbing and swelling. This study aimed to 
determine whether topical halometasone can be used to reduce these acute adverse effects for 
post-PDL care of patients. 
Methods: A total of 40 PWS subjects were enrolled in this study and randomly assigned into two 
regimens: PDL alone and PDL + halometasone. All subjects were given a single treatment of PDL 
with wavelength of 595 nm, fluence of 8.0~13.5 J/cm2, pulse duration of 0.45~20 ms (We mainly 
used purpuric pulse duration for PWS) and spot size of 7 mm. Subjects in the PDL + halometasone 
group received topical application of halometasone daily for 3 days. Subjects were followed-up on 
days 3, 7 and one month post-PDL to evaluate the reduction of adverse effects. 
Results: Subjects in the PDL + halometasone group had significantly improved erythema and 
scab scores and had less erythema duration days as compared to those in the PDL alone group. 
Topical halometasone also showed a decrease in pain index among subjects, but was statistically 
insignificant. Topical halometasone did not affect the ultimate efficacy of PDL treatment for PWS. 
Conclusion: Topical halometasone can significantly reduce acute adverse effects induced by PDL 
for treatment of PWS birthmarks, thus providing a safe and efficacious solution for post-PDL care 
of PWS patients.
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In this study, we hypothesized that topical halometasone 
could significantly reduce PDL-induced acute adverse 
effects for treatment of PWS birthmarks.
Patients and Methods
Forty patients with diagnosis of PWS were recruited from 
the Outpatient Clinic of Dermatology at the author’s 
institution. The subjects were randomly assigned into 2 
groups: PDL alone and PDL + halometasone. All subjects 
received a single dose of PDL treatment on their PWS 
lesions with a wavelength of 595 nm, fluence of 8.0~13.5 
J/cm2, pulse duration of 0.45~20 ms (We mainly used 
purpuric pulse duration for PWS), DCD 30/20 and spot size 
of 7 mm (Vbeam-Perfecta, Candela, Wayland, MA). The 
subjects in the PDL + halometasone group were instructed 
to apply a 1 mm thin layer of topical halometasone cream 
(0.05% w/w [6α, 11β, 16α]-2-chloro-6, 9-difluoro-11, 17, 
21-trihydroxy-16-methylpregna-1, 4-diene-3,20-dione; 
Bright Future Pharmaceutical Laboratories Ltd., Hong 
Kong, China) over PDL-treated areas daily for 3 days. 
The subjects in the PDL alone group received topical 
vaseline cream as the placebo control. All subjects were 
followed-up on days 3, 7 and one month post-PDL to 
evaluate reduction of adverse effects. Photos were taken 
during each follow-up visit. The duration days of existing 
pain, erythema, scabbing and swelling were recorded. The 
indexes of pain, swelling, erythema and scabbing were 
scored on the third day post-PDL based on severity on a 
1 to 4 scale (1: none or 1~25% severity degree; 2: mild or 
25~50%; 3: moderate or 50~75%; 4: severe or 75~100%). 
The evaluations were performed by two independent 
dermatologists. Statistical analysis was performed using 
a paired t test with SPSS software (version 15.0, Chicago, 
IL). P value < 0.05 was considered statistically significant.
Results and Discussion
All 40 subjects completed the 1-month protocol 
and follow-up evaluations. There was no statistical 
significance in subject age, lesion size and lesion color 
between the 2 groups (Table 1). All the subjects reported 
that the pain from the PWS lesions post-PDL treatment 
lasted for about one day. Topical halometasone showed a 
reduction in the pain index of the PDL + halometasone 
group as compared to the PDL alone group, but it was not 
statistically significant (1.2 ± 0.41 vs. 1.4 ± 0.50, P = 0.0881, 
Table 1). There was no difference in swelling days and 
scores between the 2 groups (Table 1). The subjects in 
the PDL + halometasone group showed a significantly 
lower erythema score and shorter erythema duration 
time than those in the PDL alone group (erythema scores: 
0.4 ± 0.82 vs. 0.9 ± 0.91, P = 0.0381; erythema duration 
dates: 3.7 ± 8.11 vs. 7.3 ± 10.49, P = 0.0494; Table 1 & 
Figure 1). Topical halometasone also showed a significant 
reduction of scab scores in the PDL + halometasone 
group as compared to the PDL alone group (1.15 ± 0.77 
vs. 1.65 ± 1.22, P = 0.0486, Table 1 & Figure 1). There was 
no significant change in the duration time of scabbing 
between the 2 groups (Table 1). No hyperpigmentation 
or hypopigmentation was observed in any of the subjects. 
Halometasone 0.05% showed good tolerability in the study; 
no obvious adverse event was reported from the subjects. 
There was no significant difference in the improvement 
of bleached PWS lesion one month post-PDL between the 
2 groups, suggesting topical halometasone did not affect 
the ultimate efficacy of PDL treatment on PWS lesions 
among the subjects.
Many acute adverse effects can be produced on PWS 
lesions after PDL treatment, such as pain, swelling, 
erythema, scabbing, and changes in pigmentation. 
The majority of them will diminish within days to 2 
weeks post-PDL therapy without further treatment. 
However, these adverse effects can cause temporary, 
sometimes severe, discomfort to patients in the first week, 
especially to infantile and pediatric subjects. Therefore, 
Table 1. Comparison of PDL-Induced Acute Adverse Effects Between the PDL Alone and PDL + Halometasone Groups
Treatment Group PWS Alone PWS + Halometasone P Value
N 20 20
Age 16 ± 10.814 13 ± 8.146 0.2207
Lesion size (cm2) 29.9 ± 23.510 37.9 ± 19. 488 0.1243
Lesion color score 4.85 ± 1.136 5.6 ± 1.903 0.0692
Days for pain 1.0 ± 0.00 1.0 ± 0.00
Pain index 1.4 ± 0.50 1.2 ± 0.41 0.0881
Days for swelling 3.9 ± 1.21 3.9 ± 2.29 0.5000
Swelling score 1.0 ± 0.00 1.0 ± 0.00
Erythema score 0.9 ± 0.91 0.4 ± 0.82 0.0381
Days for erythema 7.3 ± 10.49 3.7 ± 8.11 0.0494
Scab score 1.65 ± 1.22 1.15 ± 0.77 0.0486
Days for scabbing 7.2 ± 5.82 8.7 ± 3.58 0.1744
Abbreviations: PDL, pulsed dye laser; PWS, port wine stain.
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                                                                Halometasone Reduces Side Effects on Post-PDL PWS
how to reduce PDL-induced acute adverse effects is 
a very important step for post-PDL care. Many types 
of corticosteroids have been used with PDL to reduce 
the post-PDL inflammatory response or prevent scar 
formations.20-22 However many adverse sequelae, such 
as hypopigmentation, telangiectasis, and skin atrophy, 
have been observed in a substantial portion (50%) of 
the segments treated by corticosteroid (triamcinolone 
acetonide, 5-FU) intralesionally alone.20 Furthermore, 
affordability of the prescribed corticosteroid is also a 
consideration for patients from rural China. Therefore, 
looking for a more affordable corticosteroid with 
fewer side effects is very important for many patients 
visiting our clinic. Halometasone is a potent synthetic 
corticosteroid that has been shown to be more effective 
than betamethasone in treating dermatitis.22 Due to its 
profound and strong anti-inflammatory functions, we 
hypothesized that topical Halometasone could effectively 
reduce PDL-induced acute adverse effects including pain, 
swelling, scabbing and erythema. Indeed, our results 
showed topical halometasone could significantly reduce 
the severity of scabbing and erythema induced by PDL for 
the treatment of PWS. Many clinical studies have shown 
halometasone is well tolerated.23-26 Some mild adverse 
events, such as a stinging and burning sensation, have been 
reported in some patients when halometasone is applied 
for more than 18 days.26 In this study, our purpose was to 
reduce PDL-induced adverse effects which were instant 
so that halometasone was applied only for 3 days. We did 
not observe any side effects in the participants during 
the short time of topical application. Therefore, topical 
halometasone has a good safety and tolerability profile for 
patients. Furthermore, the low cost of halometasone also 
offers an economical benefit for patients. 
In conclusion, topical halometasone is efficacious and 
safe to reduce PDL-induced acute adverse effects, such as 
pain, erythema and scabbing. The authors recommend its 
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